An Open-Label Multiple-Dose, Dose Escalation Study To Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Participants With Cervical High Grade Squamous Intraepithelial Lesions
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs ABI 1968 (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Adverse reactions
- Sponsors Antiva Biosciences
- 12 Nov 2019 Planned End Date changed from 1 Aug 2020 to 1 Jun 2020.
- 12 Nov 2019 Status changed from not yet recruiting to recruiting.
- 08 Jul 2019 Planned End Date changed from 1 Jul 2019 to 1 Aug 2020.